Roche Tempium Discontinued Following Abnormal Liver Tests In Phase III

Elevated bilirubin and liver transaminase levels in a Phase III trial led to discontinuation of development of Roche's Tempium (lazabemide). The company announced the halt of the Alzheimer's therapy program on Sept. 14.